Mehdi Ghodbane received a B.S. degree in Bioengineering from Lehigh University (2007) and a Ph.D. degree in Biomedical Engineering from Rutgers University (2014). Following graduate school, Mehdi joined GSK in 2015 as part of the Biopharmaceutical Advanced Manufacturing Technologies department, an organization focused solely on technology development. After working to advance various novel purification technologies, he began focusing on developing integrated drug substance manufacturing in 2016. He has been heavily involved since early conceptualization through design, construction, installation, commissioning, and proof-of-concept of GSK’s R&D continuous processing facility. In parallel, Mehdi has led efforts to develop unit operations suitable for integration within an intensified, continuous or semi-continuous framework. He joined the Downstream Process Development group in 2019 and has recently been appointed as the Scientific Lead of Integrated Drug Substance Manufacture at GSK. In this position, Mehdi provides oversight and active management of the integrated downstream platform team and overall program, with a clear focus on delivering near- and long-term strategy for development of a GMP-ready downstream platform